search
Back to results

Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment

Primary Purpose

Alzheimer's Disease, Mild Cognitive Impairment, Healthy

Status
Unknown status
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Levodopa
Sponsored by
University Hospital Muenster
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer's Disease focused on measuring Dementia, Mild Cognitive Impairment, MCI, levodopa, learning, enhancement

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria for patients with dementia: Patients: clinical diagnosis of AD or mild cognitive impairment primary language German Exclusion Criteria for healthy subjects and patients with dementia/MCI: Known allergy to levodopa or tetrazine History of medication/drug abuse Acute nicotine withdrawal or > 15 cigarettes per day > 6 cups/glasses of coffee, caffeine drinks or energy drinks per day > 50 grams of alcohol per day Severe hypertonia (systole >160 mm Hg) Severe arteriosclerosis Diabetes, asthma, or glaucoma Severe hearing disability no focal brain lesions Premorbid depression or psychosis Medication with dopamine agonists or antagonists Parkinsonian symptoms

Sites / Locations

  • University of Muenster, Department of NeurologyRecruiting

Outcomes

Primary Outcome Measures

Cognitive performance assessed by neuropsychological tests and learning paradigms under placebo and levodopa in healthy subjects and patients with dementia or Mild Cognitive Impairment.
Brain activity pattern during learning under levodopa as compared to placebo in healthy subjects.

Secondary Outcome Measures

Long-term stability of learning performance after 1 month in healthy subjects.

Full Information

First Posted
March 21, 2006
Last Updated
October 24, 2007
Sponsor
University Hospital Muenster
search

1. Study Identification

Unique Protocol Identification Number
NCT00306124
Brief Title
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
Official Title
Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2007
Overall Recruitment Status
Unknown status
Study Start Date
January 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2008 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
University Hospital Muenster

4. Oversight

5. Study Description

Brief Summary
This study aims to determine whether levodopa is effective in boosting learning and memory in healthy subjects and patients with dementia or Mild Cognitive Impairment. We also examine in healthy subjects using functional magnetic resonance imaging which brain regions mediate improved learning after levodopa administration.
Detailed Description
Prior work of our group shows that the dopamine precursor levodopa markedly improves word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind trial, we probe whether administration of levodopa improves learning performance as compared to placebo administration on neuropsychological tests and in an associative learning paradigm. We postulate that levodopa improves learning success and memory performance in healthy subjects, while the effect in patients with dementia or Mild Cognitive Impairment might depend on other factors, including severity of memory impairment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer's Disease, Mild Cognitive Impairment, Healthy
Keywords
Dementia, Mild Cognitive Impairment, MCI, levodopa, learning, enhancement

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Levodopa
Primary Outcome Measure Information:
Title
Cognitive performance assessed by neuropsychological tests and learning paradigms under placebo and levodopa in healthy subjects and patients with dementia or Mild Cognitive Impairment.
Title
Brain activity pattern during learning under levodopa as compared to placebo in healthy subjects.
Secondary Outcome Measure Information:
Title
Long-term stability of learning performance after 1 month in healthy subjects.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for patients with dementia: Patients: clinical diagnosis of AD or mild cognitive impairment primary language German Exclusion Criteria for healthy subjects and patients with dementia/MCI: Known allergy to levodopa or tetrazine History of medication/drug abuse Acute nicotine withdrawal or > 15 cigarettes per day > 6 cups/glasses of coffee, caffeine drinks or energy drinks per day > 50 grams of alcohol per day Severe hypertonia (systole >160 mm Hg) Severe arteriosclerosis Diabetes, asthma, or glaucoma Severe hearing disability no focal brain lesions Premorbid depression or psychosis Medication with dopamine agonists or antagonists Parkinsonian symptoms
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bernward Winter, MSc
Phone
+49-251-83
Ext
45695
Email
bwinter@uni-muenster.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan Knecht, MD
Organizational Affiliation
Neurology, University of Muenster, Germany
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Caterina Breitenstein, PhD
Organizational Affiliation
Neurology, University of Muenster, Germany
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Julia Reinholz, PhD
Organizational Affiliation
Neurology, University of Muenster, Germany
Official's Role
Study Director
Facility Information:
Facility Name
University of Muenster, Department of Neurology
City
Muenster
State/Province
North-Rhine Westphalia
ZIP/Postal Code
48129
Country
Germany
Individual Site Status
Recruiting

12. IPD Sharing Statement

Citations:
PubMed Identifier
15236398
Citation
Knecht S, Breitenstein C, Bushuven S, Wailke S, Kamping S, Floel A, Zwitserlood P, Ringelstein EB. Levodopa: faster and better word learning in normal humans. Ann Neurol. 2004 Jul;56(1):20-6. doi: 10.1002/ana.20125.
Results Reference
background
PubMed Identifier
12596014
Citation
Breitenstein C, Knecht S. [Language acquisition and statistical learning]. Nervenarzt. 2003 Feb;74(2):133-43. doi: 10.1007/s00115-002-1466-1. German.
Results Reference
background
PubMed Identifier
16087920
Citation
Floel A, Hummel F, Breitenstein C, Knecht S, Cohen LG. Dopaminergic effects on encoding of a motor memory in chronic stroke. Neurology. 2005 Aug 9;65(3):472-4. doi: 10.1212/01.wnl.0000172340.56307.5e.
Results Reference
background

Learn more about this trial

Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment

We'll reach out to this number within 24 hrs